Table 4 The frequency of HIF1α isoforms in benign prostate hyperplasia and prostate cancer with and without NE.
Table 4 | Total nr. | HIF1α 1.1 | HIF1α 1.2 | HIF1α 1.3 | HIF1α 12+ | HIF1α 12- | HIF1α 11-&12- | HIF1α 14+ | HIF1α 14- |
|---|---|---|---|---|---|---|---|---|---|
Benign | 8 | 8 (100%) | 8 (100%) | 0 | 8 (100%) | 8 (100%) | 8 (100%) | 8 (100%) | 8 (100%) |
Adenocarcinoma | 43 | 43 (100%) | 25 (58%) | 0 | 43 (100%) | 43 (100%) | 43 (100%) | 43 (100%) | 43 (100%) |
Adenocarcinoma immunopositive for HIF1α | 26 | 26 (100%) | 24 (92%) | 0 | 26 (100%) | 26 (100%) | 26 (100%) | 26 (100%) | 26 (100%) |
Adenocarcinoma immunonegative for HIF1α | 17 | 17 (100%) | 1 (6%) | 0 | 17 (100%) | 17 (100%) | 17 (100%) | 17 (100%) | 17 (100%) |
Adenocarcinoma with NE | 22 | 22 (100%) | 19 (86%) | 0 | 22 (100%) | 22 (100%) | 22 (100%) | 22 (100%) | 22 (100%) |
Adenocarcinoma Without NE | 21 | 21 (100%) | 6 (28%) | 0 | 21 (100%) | 21 (100%) | 21 (100%) | 21 (100%) | 21 (100%) |
LNCaP | + | - | - | + | + | + | + | + |